Ushbu ish iqtibos qilgan ishlar

163 ta ish

Ish: Translational research of new developments in targeted therapy of colorectal cancer

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram +3
Maqola201834 iqtibos
ABI
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi, Steven O’Day, David F. McDermott +26
Maqola20109 iqtibos
ABI
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Robert D. Schreiber, Lloyd J. Old, Mark J. Smyth
Sharh maqola20115 iqtibos
ABI
Comprehensive review of targeted therapy for colorectal cancer
Yuanhong Xie, Yingxuan Chen, Jing‐Yuan Fang
Sharh maqola20205 iqtibos
ABI
Sarlavhasiz
Boshqa4 iqtibos
ABI
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Herbert I. Hurwitz, Louis Fehrenbacher, William Novotny +12
Maqola20044 iqtibos
ABI
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Jérôme Galon, Anne Costes, Fátima Sánchez‐Cabo +13
Maqola20064 iqtibos
ABI
Diagnosis and Treatment of Metastatic Colorectal Cancer
Leah H. Biller, Deborah Schrag
Sharh maqola20214 iqtibos
ABI
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Rakesh K. Jain
Sharh maqola20013 iqtibos
ABI
Molecular targeted therapy: Treating cancer with specificity
Yeuan Ting Lee, Yi Jer Tan, Chern Ein Oon
Sharh maqola20183 iqtibos
ABI
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Julie R. Brahmer, Karen L. Reckamp, Paul Baas +22
Maqola20153 iqtibos
ABI
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey, Eric Van Cutsem, Alberto Sobrero +17
Maqola20123 iqtibos
ABI
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
Michael J. Overman, Sara Lonardi, Ka Yeung Mark Wong +17
Maqola20183 iqtibos
ABI
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Lei Zhong, Yueshan Li, Liang Xiong +8
Sharh maqola20213 iqtibos
ABI
Strategies for enzyme/prodrug cancer therapy.
Guo Xu, Howard L. McLeod
Maqola20012 iqtibos
ABI
An overview of targeted cancer therapy
V. Vijaya Padma
Maqola20152 iqtibos
ABI
Sarlavhasiz
Boshqa2 iqtibos
ABI
Use of Real‐World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design
Simon Dagenais, Leo Russo, Ann Madsen +2
Sharh maqola20212 iqtibos
ABI
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Rakesh K. Jain
Sharh maqola20052 iqtibos
ABI
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
Bruno Sangro, Carlos Gómez-Martín, Manuel de la Mata +11
Maqola20132 iqtibos
ABI
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?
Giuseppe Bronte, Nicola Silvestris, Marta Castiglia +10
Sharh maqola20152 iqtibos
ABI
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
Caroline Robert, Georgina V. Long, Benjamin Brady +25
Maqola20142 iqtibos
ABI
Phase II Study of the Anti-Cytotoxic T-Lymphocyte–Associated Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal Cancer
Ki Y. Chung, Ira Gore, Lawrence Fong +8
Maqola20102 iqtibos
ABI
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Leonard B. Saltz, John V. Cox, Charles D. Blanke +9
Maqola20002 iqtibos
ABI
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman, Ray McDermott, Joseph L. Leach +13
Maqola20172 iqtibos
ABI